Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
暂无分享,去创建一个
D. Wong | F. Bymaster | L. Thompson | S. Hemrick-Luecke | D. Nelson | P. Threlkeld | J. Shaw | David L Nelson | Frank P Bymaster | Laura J Dreshfield-Ahmad | Penny G Threlkeld | Janice L Shaw | Linda Thompson | Susan K Hemrick-Luecke | David T Wong | L. Dreshfield-Ahmad
[1] I. Anderson,et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. , 2000, Journal of affective disorders.
[2] C. Montigny,et al. Current advances and trends in the treatment of depression. , 1994, Trends in pharmacological sciences.
[3] T. Branchek,et al. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.
[4] J. Nelson. Augmentation strategies with serotonergic-noradrenergic combinations. , 1998, The Journal of clinical psychiatry.
[5] S. Troy,et al. Pharmacokinetic Interaction Between Multiple‐Dose Venlafaxine and Single‐Dose Lithium , 1996, Journal of clinical pharmacology.
[6] G. Debonnel,et al. Venlafaxine: Discrepancy between in vivo 5‐HT and NE reuptake blockade and affinity for reuptake sites , 1999, Synapse.
[7] J. Mendels,et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. , 1993, Psychopharmacology bulletin.
[8] J. Schildkraut,et al. The catecholamine hypothesis of affective disorders. A review of supporting evidence. , 1967, International journal of psychiatry.
[9] K. Bergmann,et al. Combination Treatment with Noradrenalin and Serotonin Reuptake Inhibitors in Resistant Depression , 1992, British Journal of Psychiatry.
[10] C. Mazure,et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. , 1991, Archives of general psychiatry.
[11] D. Nelson,et al. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. , 1996, The Journal of pharmacology and experimental therapeutics.
[12] F. Bloom,et al. Psychopharmacology: The Fourth Generation of Progress , 1995 .
[13] E. Richelson,et al. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.
[14] T. Branchek,et al. Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Wong,et al. Antagonism of Serotonin 5‐HT1A Receptors Potentiates the Increases in Extracellular Monoamines Induced by Duloxetine in Rat Hypothalamus , 1996, Journal of neurochemistry.
[16] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[17] B. Walsh,et al. Tricyclic nonresponders: phenomenology and treatment. , 1986, The American journal of psychiatry.
[18] R. Fuller,et al. Selective inhibition of monoamine oxidase in rat brain mitochondria. , 1970, Biochemical pharmacology.
[19] M. Millan,et al. WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. , 1998, European journal of pharmacology.
[20] A. Katoh,et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. , 1995, The Journal of pharmacology and experimental therapeutics.
[21] I. Lucki,et al. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test , 1998, Psychopharmacology.
[22] M. Millan,et al. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. , 1997, Journal of neurochemistry.
[23] J. Haskins,et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. , 1986, Biochemical pharmacology.
[24] M. Berk,et al. An open‐label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM‐III-R major depressive disorder , 1997 .
[25] D. Wong,et al. Simultaneous Increases of Extracellular Monoamines in Microdialysates from Hypothalamus of Conscious Rats by Duloxetine, a Dual Serotonin and Norepinephrine Uptake Inhibitor , 1995, Neuropsychopharmacology.
[26] G. Aghajanian,et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. , 1990, Archives of general psychiatry.
[27] K. Perry,et al. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. , 1989, The Journal of pharmacology and experimental therapeutics.
[28] F. Artigas. Selective Serotonin/Noradrenal Reuptake Inhibitors (SNRIs) , 1995 .
[29] F. Monsma,et al. Functional and Radioligand Binding Characterization of Rat 5-HT6 Receptors Stably Expressed in HEK293 Cells , 1997, Neuropharmacology.
[30] D. Wong,et al. LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake , 1993, Neuropsychopharmacology.
[31] R. Fuller,et al. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. , 1994, The Journal of pharmacology and experimental therapeutics.
[32] D. Wong,et al. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. , 1995, Life sciences.
[33] T. Branchek,et al. Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. , 1991, Molecular pharmacology.
[34] R. Salomon,et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. , 1993, Psychopharmacology bulletin.
[35] J. Feighner,et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. , 1994, The Journal of clinical psychiatry.
[36] A. Gobert,et al. α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .
[37] J. Rosenbaum,et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. , 1989, The Journal of clinical psychiatry.
[38] G. Debonnel,et al. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. , 1998, European journal of pharmacology.
[39] C. de Montigny,et al. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. , 1996, The Journal of pharmacology and experimental therapeutics.
[40] M. Ikeda,et al. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. , 1995, The Journal of pharmacology and experimental therapeutics.
[41] H. Kao,et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] R. Blakely,et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.
[43] D. Wong. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. , 1998, Expert opinion on investigational drugs.